Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience

Synergistic activity between maintenance temozolomide (TMZm) and individualized multimodal immunotherapy (IMI) during/after first-line treatment has been suggested to improve the overall survival (OS) of adults with IDH1 wild-type MGMT promoter-unmethylated (unmeth) GBM. We expand the data and inclu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-02, Vol.15 (4), p.1194
Hauptverfasser:	Van Gool, Stefaan W, Makalowski, Jennifer, Van de Vliet, Peter, Van Gool, Stefanie, Sprenger, Tobias, Schirrmacher, Volker, Stuecker, Wilfried
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antigens Apoptosis Cancer therapies Care and treatment Cell cycle Cell death Chemotherapy Clinical trials Dendritic cells Glioblastoma Glioblastoma multiforme Immune system Immunogenicity Immunotherapy Lymphocytes Methods Neurosurgery Newcastle disease Oncolysis Patients Side effects Temozolomide Tumors Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!